Evidence map›Paper›PMID 39732483›Full record

ArticleBMJ open2024

Prediction of functional remission in patients with schizophrenia after antipsychotic discontinuation (FURSAD): protocol for a real-world case-control study.

Chang Lu, Yuke Dong, Zhaolin Zhai, Tianhao Gao, Mengyi Luo, Tienan Feng, Xiangyi Ma, Di Chang, Jing Chen, Jingxin Xue and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05667961 (Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05667961 completednot on this map

Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation: a Case-control Study

TypeobservationalSponsorShanghai Mental Health CenterRan2022 to 2025Enrolled480ConditionsSchizophrenia
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chang Lu *Huashan Hospital Fudan University, Shanghai, China.
Yuke Dong *Huashan Hospital Fudan University, Shanghai, China.
Zhaolin Zhai *Huashan Hospital Fudan University, Shanghai, China.
Tianhao GaoHuashan Hospital Fudan University, Shanghai, China.
Mengyi LuoHuashan Hospital Fudan University, Shanghai, China.
Tienan FengClinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-7770-3714
Xiangyi MaShanghai Mental Health Center, Shanghai, China.
Di ChangHuashan Hospital Fudan University, Shanghai, China.
Jing ChenHuashan Hospital Fudan University, Shanghai, China.
Jingxin XueHuashan Hospital Fudan University, Shanghai, China.
Yuqing ZhaoHuashan Hospital Fudan University, Shanghai, China.
Xuan LiShanghai Mental Health Center, Shanghai, China.
Chunhong ShaoHuashan Hospital Fudan University, Shanghai, China liudengtang@smhc.org.cn chunhongshao@fudan.edu.cn.
Dengtang LiuHuashan Hospital Fudan University, Shanghai, China liudengtang@smhc.org.cn chunhongshao@fudan.edu.cn.ORCID http://orcid.org/0000-0002-0813-6848

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough maintenance treatment is recommended for the prevention of relapse, in real-world settings, a subset of patients discontinue antipsychotics while having a good prognosis. The prediction of functional remission in patients with schizophrenia after antipsychotic discontinuation (FURSAD) study aims to obtain real-world knowledge regarding the characteristics of schizophrenia (SCZ) patients who achieve functional remission after antipsychotic discontinuation for 1 year or more. This study also aims to establish a prediction model to identify patients likely to benefit from antipsychotic discontinuation. METHODS AND ANALYSIS: The FURSAD study employs a real-world case-control design. Researchers will first screen patients with a diagnosis of SCZ (ICD-10) from the Shanghai Mental Health Center discharged patient pool to identify 480 participants who have been off-antipsychotic for at least 1 year. They will be assigned to the functional remission group or the functional non-remission group according to their social functioning assessment scores, including the self-assessment questionnaire WHO Quality of Life abbreviated version (WHOQoL-BREF) and the peer-assessment scale Functional Remission of General Schizophrenia (FROGS) Scale. Sociodemographic, symptom and treatment information of participants during their hospitalisation and after discharge will be extracted from the Hospital Information System and collected via interviews, respectively, to find independent variables for good prognosis after antipsychotic discontinuation. A nomogram will visualise the prediction model results to help psychiatrists make decisions. ETHICS AND DISSEMINATION: Full ethical approval for the study (study design, data acquisition license and informed consent) was granted by the ethics committee at Shanghai Mental Health Center, Shanghai, China (approval letter number: 2022-59). The findings of the FURSAD study will be published in peer-reviewed journals or disseminated in conference presentations. TRIAL REGISTRATION NUMBER: NCT05667961.

Indexed as

Antipsychotic AgentsRemission InductionSchizophreniaAdultCase-Control StudiesChinaFemaleHumansMaleMiddle AgedPrognosisQuality of LifeResearch DesignAntipsychotic AgentsCase-Control StudiesDrug TherapyQuality of LifeSchizophrenia & psychotic disorders

Identifiers

PMID39732483
PMCPMC11683939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.